首页> 外文期刊>Nanomedicine >Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents
【24h】

Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents

机译:用于siRNA递送以及siRNA与其他治疗剂共同递送的纳米载体

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

A major problem in cancer treatment is the multidrug resistance. siRNA inhibitors have great advantages to solve the problem, if the bottleneck of their delivery could be well addressed by the various nanocarriers. Moreover, co-delivery of siRNA together with the various anticancer agents in one nanocarrier may maximize their additive or synergistic effect. This review provides a comprehensive summary on the state-of-the-art of the nanocarriers, which may include prodrugs, micelles, liposomes, dendrimers, nanohydrogels, solid lipid nanoparticles, nanoparticles of biodegradable polymers and nucleic acid nanocarriers for delivery of siRNA and co-delivery of siRNA together with anticancer agents with focus on synthesis of the nanocarrier materials, design and characterization, in vitro and in vivo evaluation, and prospect and challenges of nanocarriers.
机译:癌症治疗中的主要问题是多药耐药性。如果各种纳米载体都能很好地解决其递送瓶颈,则siRNA抑制剂具有解决该问题的巨大优势。此外,在一个纳米载体中共同递送siRNA和各种抗癌剂可以最大化其加和或协同作用。这篇综述提供了有关纳米载体最新技术的全面总结,其中可能包括前药,胶束,脂质体,树状聚合物,纳米水凝胶,固体脂质纳米颗粒,可生物降解的聚合物纳米颗粒以及用于递送siRNA和co的核酸纳米载体siRNA与抗癌药的联合交付,重点在于纳米载体材料的合成,设计和表征,体外和体内评估以及纳米载体的前景和挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号